ADVERTISEMENT

novel treatments

Research in Review

Immunotherapy Drug Improves Overall Survival in Patients With NSCLC

12/30/2015

JCP Editors

Favorable results for pembrolizumab, a PD-1/PD-L1 inhibitor only recently approved for the treatment of non-small-cell lung cancer (NSCLC), were found in a trial comparing the drug’s effectiveness to that of the...

Favorable results for pembrolizumab, a PD-1/PD-L1 inhibitor only recently approved for the treatment of non-small-cell lung cancer (NSCLC), were found in a trial comparing the drug’s effectiveness to that of the...

...

12/30/2015

Journal of Clinical Pathways

Research in Review

Novel Lung Cancer Vaccine Beneficial, but Only for Certain Patients

11/06/2015

JCP Editors

A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and...

A study of a new novel vaccine for the treatment of non-small cell lung cancer (NSCLC) may have found potential benefits for specific patients who initiate immunotherapy within 12 weeks of completing chemotherapy and...

A...

11/06/2015

Journal of Clinical Pathways

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Advertisement

Advertisement

Advertisement

Upcoming Events

September 21 ⁠–⁠ September 22

AMP Europe

September 30 ⁠–⁠ October 2

October 1 ⁠–⁠ October 2

October 2 ⁠–⁠ October 5

October 5 ⁠–⁠ October 6

October 14 ⁠–⁠ October 16

October 16 ⁠–⁠ October 19

October 19 ⁠–⁠ October 20

October 26 ⁠–⁠ October 27

October 29 ⁠–⁠ November 2

See Full Calendar

Advertisement

Advertisement